ClinicalTrials.gg
TerminatedNCT06055075Updated Sep 29, 2026Results posted

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1/2 interventional study of Forimtamig and Carfilzomib in Relapsed or Refractory Multiple Myeloma, sponsored by Hoffmann-La Roche. Terminated at 8 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.
Updated Sep 29, 2026Now TerminatedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Multiple Myeloma by Hoffmann-La Roche — 6 open to participants now, 12 under way, 1 of them phase 3. Multiple Myeloma · Hoffmann-La Roche.

Enrollment
24th of 29
21 · median 90
Started
2023
with 3 others
Phase 1/2
5 of 30
1 open now
Registered
25th of 30
by date

Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, this one is the 24th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 1/2, and was the 25th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 30 studies in Multiple Myeloma by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Multiple Myeloma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

04

In context

Multiple Myeloma Reclassified

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

This study's enrollment of 21 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0 or 1
  • of at least 12 weeks
  • Documented diagnosis of MM according to the IMWG diagnostic criteria
  • Evidence of progressive disease based on Investigator's determination of response by IMWG criteria on or after last dosing regimen
  • AEs from prior anti-cancer therapy resolved to Grade ≤ 1,
  • Adequate organ functions

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after the last dose of study drug
  • Plasma cell leukemia with circulating plasma cell count ≥ 5% or >500/microliter (µL)
  • Participants with known amyloidosis
  • Participants with myelodysplastic syndrome
  • Prior treatment with monoclonal antibody (mAb) and antibody-drug conjugate within 4 weeks or 5 half-lives of the drug, whichever is shorter
  • Prior anti-cancer therapy (chemotherapy, small molecule/tyrosine kinase inhibitors, radiotherapy) within 14 days prior to first forimtamig administration
  • Prior solid organ transplantation
  • Active auto-immune disease or flare within 6 months prior to start of study treatment
  • Known or suspected chronic active Epstein-Barr virus (EBV) infection
  • virus (HBV) infection
  • Acute or chronic virus (HCV) infection
  • Known history of seropositivity
  • (s) within one month prior to start of the treatment
  • Participants not fully vaccinated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as per local recommendations
  • Previous refractoriness to carfilzomib
  • Participants who discontinued prior carfilzomib treatment due to treatment-related toxicity
  • Participants with known liver cirrhosis
  • Participants eligible for stem cell transplantation (SCT) or autologous SCT at the time of enrollment for Study BP43437 are excluded
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Dose Exploration Phase: Forimtamig (Dose 1) + Carfilzomib

    Participants will receive Dose 1 of forimtamig, subcutaneous (SC) injection in combination with carfilzomib, intravenous (IV) infusion until disease progression.

    Drug: Forimtamig · Drug: Carfilzomib

  • Experimental
    Dose Exploration Phase: Forimtamig (Dose 2) + Carfilzomib

    Participants will receive Dose 2 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.

    Drug: Forimtamig · Drug: Carfilzomib

  • Experimental
    Dose Exploration Phase: Forimtamig (Dose 3) + Carfilzomib

    Participants will receive Dose 3 of forimtamig, SC injection in combination with carfilzomib, IV infusion until disease progression.

    Drug: Forimtamig · Drug: Carfilzomib

  • Experimental
    Dose Exploration Phase: Forimtamig (Dose 1) + Daratumumab

    Participants will receive Dose 1 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.

    Drug: Forimtamig · Drug: Daratumumab

  • Experimental
    Dose Exploration Phase: Forimtamig (Dose 2) + Daratumumab

    Participants will receive Dose 2 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.

    Drug: Forimtamig · Drug: Daratumumab

  • Experimental
    Dose Exploration Phase: Forimtamig (Dose 3) + Daratumumab

    Participants will receive Dose 3 of forimtamig, SC injection in combination with daratumumab, SC injection until disease progression.

    Drug: Forimtamig · Drug: Daratumumab

  • Experimental
    Dose Expansion Phase: Forimtamig

    Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase until disease progression or completion of 12 months of treatment, whichever occurs first.

    Drug: Forimtamig

  • Experimental
    Dose Expansion Phase: Forimtamig + Carfilzomib

    Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase in combination with carfilzomib, IV infusion until disease progression.

    Drug: Forimtamig · Drug: Carfilzomib

  • Experimental
    Dose Expansion Phase: Forimtamig + Daratumumab

    Participants will receive forimtamig, SC injection at a fixed dose determined during dose exploration phase in combination with daratumumab, SC injection until disease progression.

    Drug: Forimtamig · Drug: Daratumumab

Interventions

  • DrugForimtamig

    Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

  • Carfilzomib will be administered via IV infusion in combination with forimtamig.

  • Daratumumab will be administered via SC injection in combination with forimtamig.

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Effects (AEs)

    AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: From initiation of study treatment up to approximately 15.7 months

  2. Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined According to American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading

    CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, headache, and myalgia and may also include hypotension, capillary leak (hypoxia), dyspnea, chest discomfort and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS.

    Time frame: From initiation of study treatment up to approximately 15.7 months

  3. Number of Participants With Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), With Severity Determined According to ASTCT Consensus Grading

    ICANS grade is determined by the most severe event (immune effector cell-associated encephalopathy \[ICE\] score, level of consciousness, seizures, motor findings, raised intracranial pressure \[ICP\]/cerebral edema) not attributed to any other cause. Grade 1=ICE score of 7-9; awakens spontaneously; no seizure/motor findings/elevated ICP/cerebral edema. Grade 2=ICE score of 3-6; awakes voice; no seizure/motor findings/elevated ICP/cerebral edema. Grade 3=ICE score of 0-2; awakes only to tactile stimulus; any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizure on EEG that resolves with intervention; no motor findings; focal/local edema on neuroimaging.

    Time frame: From initiation of study treatment up to approximately 15.7 months

  4. Investigator-assessed Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria

    ORR=percentage of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG response criteria. CR \& sCR are defined as outlined in endpoint 5 (CRR/sCRR). VGPR=serum \& urine M-protein (UMP) detectable by immunofixation, but not electrophoresis; ≥90% reduction in serum M-protein (SMP) + UMP level \<100 mg/24 hrs; at baseline ≥90% reduction in sum of the maximal perpendicular diameter (SPD) compared with baseline for soft tissue plasmacytoma \& ≥90% decrease in the difference between involved \& uninvolved SFLC levels. PR=≥50% reduction in SMP \& UMP reduction ≥90% or \<200 mg/24hours; if SMP \& UMP not measurable, ≥50% decrease in involved \& uninvolved SFLC difference in place of M-protein criteria; if SMP, UMP \& SFLC assay not unmeasurable, ≥50% reduction in plasma cells required in place of M-protein (baseline BM plasma cell ≥30%); at baseline, a ≥50% reduction in SPD of soft tissue plasmacytomas.

    Time frame: Up to approximately 15.2 months

  5. Investigator-assessed Complete Response Rate (CRR) / Stringent Complete Response Rate (sCRR) Per IMWG Response Criteria

    CRR and sCRR were defined as the percentage of participants with CR or sCR, as determined by the investigator per IMWG response criteria. CR was defined as: no evidence of initial monoclonal protein isotype(s) on immunofixation of the serum \& urine; Disappearance of any soft tissue plasmacytomas; \<5% plasma cells in BM \& a normal SFLC ratio of 0.26-1.65. sCR was defined as: CR (defined above); normal SFLC ratio, \& absence of clonal cells in BM by IHC or negative by 2-4 color flow cytometry. CR and sCR are distinct response categories and are evaluated and reported separately in accordance with the defined response criteria i.e., if a response is clinically upgraded from CR to sCR it is not further considered a CR but solely a sCR. Percentages have been rounded off.

    Time frame: Up to approximately 15.2 months

  6. Investigator-assessed VGPR Rate or Better Per IMWG Response Criteria

    VGPR rate was defined as the percentage of participants with VGPR as determined by the investigator per IMWG response criteria. VGPR was defined as: serum \& UMP detectable by immunofixation, but not on electrophoresis; or ≥90% reduction in SMP plus UMP level \<100 mg/24 hours; at baseline ≥90% reduction in SPD compared with baseline for soft tissue plasmacytoma \& ≥90% decrease in the difference between involved \& uninvolved SFLC levels. Responses better than VGPR include CR and sCR (as defined in endpoint 5). Percentages have been rounded off.

    Time frame: Up to approximately 15.2 months

Secondary outcomes

  1. Investigator-assessed Progression-free Survival (PFS) Per IMWG Response Criteria

    PFS=time from randomization until disease progression (PD) per IMWG criteria or death from any cause. PD=any 1 or more of the following: Increase of 25% from lowest response value in any of the following: Serum M-component, Urine M-component or in participants without measurable SMP \& UMP levels: difference between involved \& uninvolved FLC levels; For non-secretory participants at study entry: in participants without measurable SMP \& UMP levels \& without measurable disease by FLC: BM plasma cell percentage irrespective of baseline status (absolute %must be ≥10%); appearance of a new lesion/s, ≥ 50% increase from nadir in SPD of \>1 lesion, or ≥50% increase in the longest diameter of a previous lesion \>1centimeters (cm) in short axis; Definite development of new bone lesions/definite increase in the size of existing bone lesions; ≥50% increase in circulating plasma cells. Kaplan-Meier (K-M) method was used to estimate the median PFS. Overall number analyzed=participants with an event.

    Time frame: Up to approximately 15.2 months

  2. Investigator-assessed Duration of Response (DoR) for Participants Who Achieved PR or Better

    DoR was defined as the time from the initial objective response (OR) (sCR, CR, PR, or VGPR) to the time of PD or death from any cause as determined by the investigator per IMWG response criteria. CR, sCR, VGPR, and PR were defined the same as outlined in the description for the primary endpoint ORR. PD was defined as outlined in the description for the endpoint PFS. K-M method was used to estimate the median DOR.

    Time frame: Up to approximately 15.2 months

  3. Investigator-assessed Time to Response (TTR) Per IMWG Response Criteria

    TTR was defined as the time from randomization until an OR (PR or better), as determined by the investigator per IMWG response criteria. CR, sCR, VGPR and PR were defined the same as outlined in the description for the primary endpoint ORR. K-M method was used to estimate the median TTR.

    Time frame: Up to approximately 15.2 months

  4. Investigator-assessed Time to Best Response (TTBR) Per IMWG Response Criteria

    TTBR was defined as the time from randomization until the best OR (sCR, CR, VGPR, or PR), as determined by the investigator per IMWG response criteria. CR, sCR, VGPR and PR were defined the same as outlined in the description for the primary endpoint ORR. K-M method was used to estimate the median TTBR.

    Time frame: Up to approximately 15.2 months

  5. Investigator-assessed Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause as determined by the investigator per IMWG response criteria. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. K-M method was used to estimate the median OS.

    Time frame: Up to approximately 15.7 months

  6. Number of Participants With Anti-drug Antibodies (ADAs) to Forimtamig

    Participants who received forimtamig were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following forimtamig exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

    Time frame: Up to approximately 15.7 months

  7. Serum Concentrations of Forimtamig at the Specified Timepoints

    Time frame: Pre-dose on Day (D)1 of Cycle (C)1,2&4, D4 of C1&5, D2C3; 4hours post-dose on D1,4 of C1, D2C3, D1C4, D4C5; D2,8,9,11,15,16&18 of C1; D2,8,15,22 of C2&4; D1,4,8,15,22 of C3; D1,8,15 of C5; D1,4,8,15 of C6,7,8&9; D1,4,8 of C10

  8. Area Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of Forimtamig

    Time frame: Up to Day 15 of Cycle 3 (1 cycle=28 days)

  9. Maximum Observed Concentration (Cmax) of Forimtamig

    Time frame: Day 1 of Cycle 3 (1 cycle=28 days)

08

Results

Posted Sep 29, 2026

Participant flow

A total of 21 participants with relapsing or refractory multiple myeloma (r/r MM) took part in the study at 9 investigative sites across Korea, Australia, Italy, New Zealand, Canada, and Spain from 08 December 2023 to 08 July 2025.

Participant flow — Overall Study
MilestoneCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Started777
Safety population766
Completed210
Not completed567
Withdrew: Death011
Withdrew: Study terminated by sponsor334
Withdrew: Withdrawal by subject211
Withdrew: Did not start study treatment011

Outcome measures

PrimaryNumber of Participants With Adverse Effects (AEs)

AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
From initiation of study treatment up to approximately 15.7 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Effects (AEs)
ParticipantsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Number of Participants With Adverse Effects (AEs)766
PrimaryNumber of Participants With Cytokine Release Syndrome (CRS), With Severity Determined According to American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading

CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, headache, and myalgia and may also include hypotension, capillary leak (hypoxia), dyspnea, chest discomfort and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS.

Time frame:
From initiation of study treatment up to approximately 15.7 months
Reported as:
Count of participants · Participants
Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined According to American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading
ParticipantsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Step-up Dose 1 - Grade 1112
Step-up Dose 1 - Grade 2010
Step-up Dose 1 - Grade 3001
Step-up Dose 2 - Grade 1344
Target Dose 1 - Grade 1023
Target Dose 1 - Grade 2100
Cycle 2 - Grade 1211
Cycle 3+ - Grade 1211
PrimaryNumber of Participants With Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), With Severity Determined According to ASTCT Consensus Grading

ICANS grade is determined by the most severe event (immune effector cell-associated encephalopathy \[ICE\] score, level of consciousness, seizures, motor findings, raised intracranial pressure \[ICP\]/cerebral edema) not attributed to any other cause. Grade 1=ICE score of 7-9; awakens spontaneously; no seizure/motor findings/elevated ICP/cerebral edema. Grade 2=ICE score of 3-6; awakes voice; no seizure/motor findings/elevated ICP/cerebral edema. Grade 3=ICE score of 0-2; awakes only to tactile stimulus; any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizure on EEG that resolves with intervention; no motor findings; focal/local edema on neuroimaging.

Time frame:
From initiation of study treatment up to approximately 15.7 months
Reported as:
Count of participants · Participants
Number of Participants With Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), With Severity Determined According to ASTCT Consensus Grading
ParticipantsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Grade 1312
Grade 2011
Grade 3100
PrimaryInvestigator-assessed Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria

ORR=percentage of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG response criteria. CR \& sCR are defined as outlined in endpoint 5 (CRR/sCRR). VGPR=serum \& urine M-protein (UMP) detectable by immunofixation, but not electrophoresis; ≥90% reduction in serum M-protein (SMP) + UMP level \<100 mg/24 hrs; at baseline ≥90% reduction in sum of the maximal perpendicular diameter (SPD) compared with baseline for soft tissue plasmacytoma \& ≥90% decrease in the difference between involved \& uninvolved SFLC levels. PR=≥50% reduction in SMP \& UMP reduction ≥90% or \<200 mg/24hours; if SMP \& UMP not measurable, ≥50% decrease in involved \& uninvolved SFLC difference in place of M-protein criteria; if SMP, UMP \& SFLC assay not unmeasurable, ≥50% reduction in plasma cells required in place of M-protein (baseline BM plasma cell ≥30%); at baseline, a ≥50% reduction in SPD of soft tissue plasmacytomas.

Time frame:
Up to approximately 15.2 months
Reported as:
Number · percentage of participants
Investigator-assessed Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria
percentage of participantsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Investigator-assessed Objective Response Rate (ORR) Per International Myeloma Working Group (IMWG) Response Criteria85.7 (42.13 to 99.64)83.3 (35.88 to 99.58)83.3 (35.88 to 99.58)
PrimaryInvestigator-assessed Complete Response Rate (CRR) / Stringent Complete Response Rate (sCRR) Per IMWG Response Criteria

CRR and sCRR were defined as the percentage of participants with CR or sCR, as determined by the investigator per IMWG response criteria. CR was defined as: no evidence of initial monoclonal protein isotype(s) on immunofixation of the serum \& urine; Disappearance of any soft tissue plasmacytomas; \<5% plasma cells in BM \& a normal SFLC ratio of 0.26-1.65. sCR was defined as: CR (defined above); normal SFLC ratio, \& absence of clonal cells in BM by IHC or negative by 2-4 color flow cytometry. CR and sCR are distinct response categories and are evaluated and reported separately in accordance with the defined response criteria i.e., if a response is clinically upgraded from CR to sCR it is not further considered a CR but solely a sCR. Percentages have been rounded off.

Time frame:
Up to approximately 15.2 months
Reported as:
Number · percentage of participants
Investigator-assessed Complete Response Rate (CRR) / Stringent Complete Response Rate (sCRR) Per IMWG Response Criteria
percentage of participantsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
sCR28.6 (3.67 to 70.96)33.3 (4.33 to 77.72)33.3 (4.33 to 77.72)
CR28.6 (3.67 to 70.96)16.7 (0.42 to 64.12)0 (0.00 to 45.93)
PrimaryInvestigator-assessed VGPR Rate or Better Per IMWG Response Criteria

VGPR rate was defined as the percentage of participants with VGPR as determined by the investigator per IMWG response criteria. VGPR was defined as: serum \& UMP detectable by immunofixation, but not on electrophoresis; or ≥90% reduction in SMP plus UMP level \<100 mg/24 hours; at baseline ≥90% reduction in SPD compared with baseline for soft tissue plasmacytoma \& ≥90% decrease in the difference between involved \& uninvolved SFLC levels. Responses better than VGPR include CR and sCR (as defined in endpoint 5). Percentages have been rounded off.

Time frame:
Up to approximately 15.2 months
Reported as:
Number · percentage of participants
Investigator-assessed VGPR Rate or Better Per IMWG Response Criteria
percentage of participantsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Investigator-assessed VGPR Rate or Better Per IMWG Response Criteria85.7 (42.13 to 99.64)83.3 (35.88 to 99.58)50.0 (11.81 to 88.19)
SecondaryInvestigator-assessed Progression-free Survival (PFS) Per IMWG Response Criteria

PFS=time from randomization until disease progression (PD) per IMWG criteria or death from any cause. PD=any 1 or more of the following: Increase of 25% from lowest response value in any of the following: Serum M-component, Urine M-component or in participants without measurable SMP \& UMP levels: difference between involved \& uninvolved FLC levels; For non-secretory participants at study entry: in participants without measurable SMP \& UMP levels \& without measurable disease by FLC: BM plasma cell percentage irrespective of baseline status (absolute %must be ≥10%); appearance of a new lesion/s, ≥ 50% increase from nadir in SPD of \>1 lesion, or ≥50% increase in the longest diameter of a previous lesion \>1centimeters (cm) in short axis; Definite development of new bone lesions/definite increase in the size of existing bone lesions; ≥50% increase in circulating plasma cells. Kaplan-Meier (K-M) method was used to estimate the median PFS. Overall number analyzed=participants with an event.

Time frame:
Up to approximately 15.2 months
Reported as:
Median · months
Investigator-assessed Progression-free Survival (PFS) Per IMWG Response Criteria
monthsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Investigator-assessed Progression-free Survival (PFS) Per IMWG Response CriteriaNA (8.9 to NA)NA (6.5 to NA)10.8 (5.6 to NA)
SecondaryInvestigator-assessed Duration of Response (DoR) for Participants Who Achieved PR or Better

DoR was defined as the time from the initial objective response (OR) (sCR, CR, PR, or VGPR) to the time of PD or death from any cause as determined by the investigator per IMWG response criteria. CR, sCR, VGPR, and PR were defined the same as outlined in the description for the primary endpoint ORR. PD was defined as outlined in the description for the endpoint PFS. K-M method was used to estimate the median DOR.

Time frame:
Up to approximately 15.2 months
Reported as:
Median · months
Investigator-assessed Duration of Response (DoR) for Participants Who Achieved PR or Better
monthsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Investigator-assessed Duration of Response (DoR) for Participants Who Achieved PR or BetterNA (6.9 to NA)NA (5.6 to NA)7.2 (4.6 to NA)
SecondaryInvestigator-assessed Time to Response (TTR) Per IMWG Response Criteria

TTR was defined as the time from randomization until an OR (PR or better), as determined by the investigator per IMWG response criteria. CR, sCR, VGPR and PR were defined the same as outlined in the description for the primary endpoint ORR. K-M method was used to estimate the median TTR.

Time frame:
Up to approximately 15.2 months
Reported as:
Median · months
Investigator-assessed Time to Response (TTR) Per IMWG Response Criteria
monthsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Investigator-assessed Time to Response (TTR) Per IMWG Response Criteria2.0 (1.4 to 2.1)1.5 (1.0 to 1.9)1.4 (1.2 to NA)
SecondaryInvestigator-assessed Time to Best Response (TTBR) Per IMWG Response Criteria

TTBR was defined as the time from randomization until the best OR (sCR, CR, VGPR, or PR), as determined by the investigator per IMWG response criteria. CR, sCR, VGPR and PR were defined the same as outlined in the description for the primary endpoint ORR. K-M method was used to estimate the median TTBR.

Time frame:
Up to approximately 15.2 months
Reported as:
Median · months
Investigator-assessed Time to Best Response (TTBR) Per IMWG Response Criteria
monthsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Investigator-assessed Time to Best Response (TTBR) Per IMWG Response Criteria4.8 (3.8 to 5.0)3.0 (1.2 to 7.8)2.9 (1.2 to 4.4)
SecondaryInvestigator-assessed Overall Survival (OS)

OS was defined as the time from randomization to death from any cause as determined by the investigator per IMWG response criteria. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. K-M method was used to estimate the median OS.

Time frame:
Up to approximately 15.7 months
Reported as:
Median · months
Investigator-assessed Overall Survival (OS)
monthsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Investigator-assessed Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to Forimtamig

Participants who received forimtamig were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following forimtamig exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Time frame:
Up to approximately 15.7 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) to Forimtamig
ParticipantsCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Number of Participants With Anti-drug Antibodies (ADAs) to Forimtamig120
SecondarySerum Concentrations of Forimtamig at the Specified Timepoints
Time frame:
Pre-dose on Day (D)1 of Cycle (C)1,2&4, D4 of C1&5, D2C3; 4hours post-dose on D1,4 of C1, D2C3, D1C4, D4C5; D2,8,9,11,15,16&18 of C1; D2,8,15,22 of C2&4; D1,4,8,15,22 of C3; D1,8,15 of C5; D1,4,8,15 of C6,7,8&9; D1,4,8 of C10
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Serum Concentrations of Forimtamig at the Specified Timepoints
nanograms per milliliter (ng/mL)Cohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Pre-dose Cycle 1 Day 1NA ± NANA ± NANA ± NA
4hours Post-dose Cycle 1 Day 1NA ± NANA ± NANA ± NA
Cycle 1 Day 26.21 ± 109.62.76 ± 94.82.44 ± 250.5
Pre-dose Cycle 1 Day 46.55 ± 50.83.69 ± 115.32.64 ± 384.1
4 hours Post-dose Cycle 1 Day 47.26 ± 52.46.99 ± 69.9NA ± NA
Cycle 1 Day 810.3 ± 44.721.4 ± 51.625.4 ± 434.0
Cycle 1 Day 913.0 ± 33.914.9 ± 589.139.3 ± 268.2
Cycle 1 Day 11NA ± NANA ± NANA ± NA
Cycle 1 Day 15NA ± NANA ± NA0.367 ± 100.8
Cycle 1 Day 1617.0 ± 13.818.9 ± NA147 ± NA
Cycle 1 Day 1823.2 ± 0.627.7 ± NA178 ± NA
Pre-dose Cycle 2 Day 10.712 ± 121.8NA ± NANA ± NA
4hours Post-dose Cycle 2 Day 12.08 ± 98.10.363 ± 120.4NA ± NA
Cycle 2 Day 23.89 ± 157.21.36 ± 83.41.57 ± 321.8
Cycle 2 Day 814.1 ± NA8.82 ± NA—
Cycle 2 Day 1523.8 ± NA——
Cycle 2 Day 2229.4 ± 34.538.6 ± NA212 ± NA
Cycle 3 Day 126.0 ± NA28.1 ± NA—
Pre-dose Cycle 3 Day 210.6 ± 72.225.6 ± 74.111.8 ± 379.4
4hours Post-dose Cycle 3 Day 211.9 ± 61.227.9 ± 97.710.2 ± 344.1
Cycle 3 Day 411.5 ± 61.320.0 ± 109.723.0 ± 319.2
Cycle 3 Day 816.1 ± 88.835.0 ± 114.625.0 ± 293.4
Cycle 3 Day 1519.2 ± 48.367.4 ± 60.543.7 ± 378.9
Cycle 3 Day 2219.2 ± 69.454.2 ± 53.032.9 ± 446.0
Pre-dose Cycle 4 Day 113.1 ± 29.628.4 ± 44.624.0 ± 401.5
4hours Post-dose Cycle 4 Day 114.8 ± 37.926.9 ± 56.944.3 ± 273.3
Cycle 4 Day 217.4 ± 29.327.9 ± 152.342.9 ± 220.0
Cycle 4 Day 820.1 ± 50.144.8 ± 61.5124 ± 11.5
Cycle 4 Day 1527.8 ± 37.461.0 ± 66.197.9 ± 25.5
Cycle 4 Day 2225.6 ± 46.460.7 ± 83.6175 ± 14.5
Cycle 5 Day 125.5 ± 42.972.8 ± 9.587.0 ± 254.2
Pre-dose Cycle 5 Day 419.8 ± 25.132.5 ± 61.239.2 ± 221.2
4hours Post-dose Cycle 5 Day 417.3 ± 15.529.7 ± 68.396.4 ± 18.8
Cycle 5 Day 819.8 ± 28.436.3 ± 40.434.0 ± 492.5
Cycle 5 Day 1523.1 ± 25.838.9 ± 83.2145 ± 4.9
Cycle 6 Day 128.0 ± 34.541.3 ± 104.3103 ± NA
Cycle 6 Day 426.4 ± 34.044.7 ± 69.966.3 ± 404.6
Cycle 6 Day 819.0 ± 31.6NA ± NA41.7 ± 113.7
Cycle 6 Day 1518.0 ± 58.820.2 ± 262.362.1 ± 133.8
Cycle 7 Day 127.6 ± 57.810.3 ± 143751.7140 ± NA
Cycle 7 Day 423.9 ± 67.173.5 ± 19.588.7 ± 104.1
Cycle 7 Day 812.4 ± 58.424.4 ± 158.976.4 ± 50.3
Cycle 7 Day 156.52 ± 265.724.9 ± NA98.2 ± 52.4
Cycle 8 Day 120.0 ± 25.852.8 ± 74.3171 ± NA
Cycle 8 Day 420.2 ± 13.053.6 ± 47.491.7 ± 60.4
Cycle 8 Day 812.1 ± 78.421.3 ± 24.878.6 ± 45.8
Cycle 8 Day 1516.4 ± 3.521.6 ± 148.2153 ± NA
Cycle 9 Day 124.0 ± 52.171.0 ± NA136 ± 19.9
Cycle 9 Day 422.9 ± 33.165.4 ± NA109 ± 23.4
Cycle 9 Day 8—32.3 ± NA121 ± NA
Cycle 9 Day 1531.6 ± 17.845.7 ± NA195 ± NA
Cycle 10 Day 119.4 ± 4.710.8 ± NA146 ± NA
Cycle 10 Day 49.30 ± NA17.8 ± NA—
Cycle 10 Day 841.4 ± NA30.8 ± NA135 ± NA
SecondaryArea Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of Forimtamig
Time frame:
Up to Day 15 of Cycle 3 (1 cycle=28 days)
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*hr/mL)
Area Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of Forimtamig
nanograms*hour/milliliter (ng*hr/mL)Cohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Area Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of Forimtamig9060 ± 34.513600 ± 92.929500 ± 348
SecondaryMaximum Observed Concentration (Cmax) of Forimtamig
Time frame:
Day 1 of Cycle 3 (1 cycle=28 days)
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of Forimtamig
ng/mLCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Maximum Observed Concentration (Cmax) of Forimtamig31.7 ± 51.257.7 ± 95.089.6 ± 263

Adverse events

Collected over From initiation of study treatment up to approximately 15.7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Arm B1: Forimtamig 0.3 mg + Carfilzomib0/7 (0%)5/7 (71.4%)7/7 (100%)
Cohort 1: Arm B2: Forimtamig 0.75 mg + Carfilzomib1/6 (16.7%)3/6 (50%)6/6 (100%)
Cohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib1/6 (16.7%)4/6 (66.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
Cytokine release syndromeImmune system disorders1/72/63/6
PyrexiaGeneral disorders2/71/62/6
PneumoniaInfections and infestations0/70/61/6
SepsisInfections and infestations1/70/61/6
Bone painMusculoskeletal and connective tissue disorders0/71/60/6
Cauda equina syndromeNervous system disorders0/71/60/6
Pleural effusionRespiratory, thoracic and mediastinal disorders0/70/61/6
Deep vein thrombosisVascular disorders0/71/60/6
Anaphylactic reactionImmune system disorders1/70/60/6
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/70/60/6
Most frequent other events
Showing 10 of 159
Most frequent other events
EventCohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + Carfilzomib
PyrexiaGeneral disorders3/75/63/6
AnaemiaBlood and lymphatic system disorders1/74/64/6
Aspartate aminotransferase increasedInvestigations0/74/60/6
DysgeusiaNervous system disorders3/74/63/6
Dry mouthGastrointestinal disorders4/70/63/6
FatigueGeneral disorders4/71/62/6
Cytokine release syndromeImmune system disorders4/73/63/6
Alanine aminotransferase increasedInvestigations0/73/61/6
Platelet count decreasedInvestigations1/73/61/6
Decreased appetiteMetabolism and nutrition disorders2/72/63/6

Baseline characteristics

Data for all participants randomized in the study have been presented.

Age, Categorical
Age, Categorical(Participants)Cohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + CarfilzomibTotal
<=18 years0000
Between 18 and 65 years24612
>=65 years5319
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + CarfilzomibTotal
Female4228
Male35513
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + CarfilzomibTotal
Hispanic or Latino0000
Not Hispanic or Latino66416
Unknown or Not Reported1135
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Arm B1: Forimtamig 0.3 mg + CarfilzomibCohort 1: Arm B2: Forimtamig 0.75 mg + CarfilzomibCohort 1: Arm B3: Forimtamig 1.5 mg + CarfilzomibTotal
American Indian or Alaska Native0000
Asian2215
Native Hawaiian or Other Pacific Islander1001
Black or African American0000
White35412
More than one race0000
Unknown or Not Reported1023
09

Study locations

8 sites
  • Princess Alexandra Hospital Woolloongabba
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Hamilton Health Sciences
    Hamilton, Ontario L8V 5C2, Canada
  • Istituto Clinico Humanitas
    Rozzano, Lombardy 20089, Italy
  • New Zealand Clinical Research - Auckland
    Auckland, 1010, New Zealand
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Seoul St Mary's Hospital
    Seoul, 06591, South Korea
  • Clinica Universitaria de Navarra
    Pamplona, Navarre 31008, Spain
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jul 2025, 19 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2023
First posted
Sep 26, 2023
StartActual
Dec 8, 2023
Primary completionActual
Jul 8, 2025
CompletionActual
Jul 8, 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.
changed Sep 29, 2026
Results
Results posted
posted Sep 29, 2026
Sites
1 site added
Show site
  • Seoul National University Hospital · Seoul, South Korea
Sep 29, 2026
Start date
Dec 12, 2023→Dec 8, 2023
Sep 29, 2026
Enrollment
19→21
Sep 29, 2026
Primary outcomes
3 edited, 3 added, 1 removed
What changed in the outcomes
  • EditedPercentageNumber of Participants withWith Adverse EventsEffects (AEs)Time frame: Up to approximately 24 months → From initiation of study treatment up to approximately 15.7 months
  • EditedInvestigator-assessed Objective Response Rate (ORR) as Determined by the Investigator perPer International Myeloma Working Group (IMWG) Response CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
  • EditedInvestigator-assessed Complete Response Rate (CRCRR) / Stringent Complete Response Rate (sCRsCRR) Rate as Determined by the Investigator perPer IMWG Response CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
  • AddedNumber of Participants With Cytokine Release Syndrome (CRS), With Severity Determined According to American Society of Transplantation and Cellular Therapy (ASTCT) Consensus GradingTime frame: From initiation of study treatment up to approximately 15.7 months
  • AddedNumber of Participants With Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), With Severity Determined According to ASTCT Consensus GradingTime frame: From initiation of study treatment up to approximately 15.7 months
  • AddedInvestigator-assessed VGPR Rate or Better Per IMWG Response CriteriaTime frame: Up to approximately 15.2 months
  • RemovedRate of Very Good Partial Response (VGPR) or Better as Determined by the Investigator per IMWG CriteriaTime frame: Up to approximately 24 months
Sep 29, 2026
Documents
Secondary outcomes
5 edited, 4 added, 2 removed
What changed in the outcomes
  • EditedInvestigator-assessed Progression-Freefree Survival (PFS) as Determined by the Investigator perPer IMWG Response CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
  • EditedInvestigator-assessed Duration of Response (DoR) for Participants who Achieve a Partial Response (Who Achieved PR) or Better as Determined by the Investigator per IMWG CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
  • EditedInvestigator-assessed Time to Best Response as Determined by the Investigator per(TTBR) Per IMWG Response CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
  • EditedSerum ConcentrationConcentrations of Forimtamig at the Specified TimepointsTime frame: Up to approximately 24 months → Pre-dose on Day (D)1 of Cycle (C)1,2&4, D4 of C1&5, D2C3; 4hours post-dose on D1,4 of C1, D2C3, D1C4, D4C5; D2,8,9,11,15,16&18 of C1; D2,8,15,22 of C2&4; D1,4,8,15,22 of C3; D1,8,15 of C5; D1,4,8,15 of C6,7,8&9; D1,4,8 of C10
  • EditedPercentageNumber of Participants withWith Anti-Drugdrug Antibodies (ADAs) to ForimtamigTime frame: Up to approximately 24 months → Up to approximately 15.7 months
  • AddedInvestigator-assessed Time to Response (TTR) Per IMWG Response CriteriaTime frame: Up to approximately 15.2 months
  • AddedInvestigator-assessed Overall Survival (OS)Time frame: Up to approximately 15.7 months
  • AddedArea Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of ForimtamigTime frame: Up to Day 15 of Cycle 3 (1 cycle=28 days)
  • AddedMaximum Observed Concentration (Cmax) of ForimtamigTime frame: Day 1 of Cycle 3 (1 cycle=28 days)
  • RemovedTime to First Response as Determined by the Investigator per IMWG CriteriaTime frame: Up to approximately 24 months
  • RemovedOverall Survival (OS) as Determined by the Investigator per IMWG CriteriaTime frame: Up to approximately 24 months
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Completed→Terminated
    Why stopped The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.
    Results posted
    1 site added
    Show site
    • Seoul National University Hospital · Seoul, South Korea
    Start date Dec 12, 2023→Dec 8, 2023
    Enrollment 19→21
    Primary outcomes 3 edited, 3 added, 1 removed
    What changed in the outcomes
    • EditedPercentageNumber of Participants withWith Adverse EventsEffects (AEs)Time frame: Up to approximately 24 months → From initiation of study treatment up to approximately 15.7 months
    • EditedInvestigator-assessed Objective Response Rate (ORR) as Determined by the Investigator perPer International Myeloma Working Group (IMWG) Response CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
    • EditedInvestigator-assessed Complete Response Rate (CRCRR) / Stringent Complete Response Rate (sCRsCRR) Rate as Determined by the Investigator perPer IMWG Response CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
    • AddedNumber of Participants With Cytokine Release Syndrome (CRS), With Severity Determined According to American Society of Transplantation and Cellular Therapy (ASTCT) Consensus GradingTime frame: From initiation of study treatment up to approximately 15.7 months
    • AddedNumber of Participants With Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), With Severity Determined According to ASTCT Consensus GradingTime frame: From initiation of study treatment up to approximately 15.7 months
    • AddedInvestigator-assessed VGPR Rate or Better Per IMWG Response CriteriaTime frame: Up to approximately 15.2 months
    • RemovedRate of Very Good Partial Response (VGPR) or Better as Determined by the Investigator per IMWG CriteriaTime frame: Up to approximately 24 months
    Secondary outcomes 5 edited, 4 added, 2 removed
    What changed in the outcomes
    • EditedInvestigator-assessed Progression-Freefree Survival (PFS) as Determined by the Investigator perPer IMWG Response CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
    • EditedInvestigator-assessed Duration of Response (DoR) for Participants who Achieve a Partial Response (Who Achieved PR) or Better as Determined by the Investigator per IMWG CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
    • EditedInvestigator-assessed Time to Best Response as Determined by the Investigator per(TTBR) Per IMWG Response CriteriaTime frame: Up to approximately 24 months → Up to approximately 15.2 months
    • EditedSerum ConcentrationConcentrations of Forimtamig at the Specified TimepointsTime frame: Up to approximately 24 months → Pre-dose on Day (D)1 of Cycle (C)1,2&4, D4 of C1&5, D2C3; 4hours post-dose on D1,4 of C1, D2C3, D1C4, D4C5; D2,8,9,11,15,16&18 of C1; D2,8,15,22 of C2&4; D1,4,8,15,22 of C3; D1,8,15 of C5; D1,4,8,15 of C6,7,8&9; D1,4,8 of C10
    • EditedPercentageNumber of Participants withWith Anti-Drugdrug Antibodies (ADAs) to ForimtamigTime frame: Up to approximately 24 months → Up to approximately 15.7 months
    • AddedInvestigator-assessed Time to Response (TTR) Per IMWG Response CriteriaTime frame: Up to approximately 15.2 months
    • AddedInvestigator-assessed Overall Survival (OS)Time frame: Up to approximately 15.7 months
    • AddedArea Under the Concentration-time Curve From Dosing to the Time of the Last Measured Concentration (AUClast) of ForimtamigTime frame: Up to Day 15 of Cycle 3 (1 cycle=28 days)
    • AddedMaximum Observed Concentration (Cmax) of ForimtamigTime frame: Day 1 of Cycle 3 (1 cycle=28 days)
    • RemovedTime to First Response as Determined by the Investigator per IMWG CriteriaTime frame: Up to approximately 24 months
    • RemovedOverall Survival (OS) as Determined by the Investigator per IMWG CriteriaTime frame: Up to approximately 24 months
    + 3 other changes: index terms, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT06055075
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Dec 8, 2023
Primary completion
Jul 8, 2025
Completion
Jul 8, 2025
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion